ES2179187T3 - Oriteuba qye se yba a cd40 para estimular una respuesta inmune. - Google Patents

Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Info

Publication number
ES2179187T3
ES2179187T3 ES96909555T ES96909555T ES2179187T3 ES 2179187 T3 ES2179187 T3 ES 2179187T3 ES 96909555 T ES96909555 T ES 96909555T ES 96909555 T ES96909555 T ES 96909555T ES 2179187 T3 ES2179187 T3 ES 2179187T3
Authority
ES
Spain
Prior art keywords
immune response
oriteuba
qye
stimulate
going
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909555T
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ES2179187T3 publication Critical patent/ES2179187T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)

Abstract

SE DESCUBRE UN METODO PARA ESTIMULAR UNA RESPUESTA INMUNITARIA QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UNA PROTEINA DE UNION A CD40. EL METODO ES UTIL EN EL TRATAMIENTO DE INDIVIDUOS INFECTADOS CON ORGANISMOS PATOGENOS U OPORTUNISTAS, E INDIVIDUOS CON UNA RESPUESTA INMUNITARIA CELULAR DISMINUIDA. LAS PROTEINAS DE UNION A CD40 INCLUYEN LIGANDO CD40, ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECIFICAMENTE A CD40 Y COMBINACIONES DE LOS MISMOS.
ES96909555T 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune. Expired - Lifetime ES2179187T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01

Publications (1)

Publication Number Publication Date
ES2179187T3 true ES2179187T3 (es) 2003-01-16

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909555T Expired - Lifetime ES2179187T3 (es) 1995-03-01 1996-02-29 Oriteuba qye se yba a cd40 para estimular una respuesta inmune.

Country Status (15)

Country Link
EP (1) EP0812206B1 (es)
JP (1) JP3657271B2 (es)
KR (1) KR19980702490A (es)
AT (1) ATE220331T1 (es)
AU (1) AU699291B2 (es)
CA (1) CA2213798C (es)
DE (1) DE69622259T2 (es)
DK (1) DK0812206T3 (es)
ES (1) ES2179187T3 (es)
FI (1) FI973484A (es)
MX (1) MX9706588A (es)
NO (1) NO973875L (es)
NZ (1) NZ305083A (es)
PT (1) PT812206E (es)
WO (1) WO1996026735A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
CA2313805A1 (en) * 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
CN1762492A (zh) * 1998-05-23 2006-04-26 莱顿大学医学中心 Cd40结合分子和ctl肽在用于***的药物组合物中的用途
EP1255560B1 (en) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40 ligand adjuvant for respiratory syncytial virus vaccine
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
JP2011502165A (ja) 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
MX341775B (es) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vectores para vacunas y metodos para potenciar respuestas inmunes.
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (en) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
ATE255906T1 (de) * 1993-10-01 2003-12-15 Immunex Corp Antikörper gegen cd40

Also Published As

Publication number Publication date
EP0812206A1 (en) 1997-12-17
DE69622259D1 (de) 2002-08-14
NO973875L (no) 1997-10-31
WO1996026735A1 (en) 1996-09-06
JPH11506418A (ja) 1999-06-08
FI973484A0 (fi) 1997-08-25
PT812206E (pt) 2002-11-29
ATE220331T1 (de) 2002-07-15
KR19980702490A (ko) 1998-07-15
NZ305083A (en) 1999-06-29
EP0812206B1 (en) 2002-07-10
FI973484A (fi) 1997-10-24
AU5301196A (en) 1996-09-18
CA2213798C (en) 2001-02-06
DK0812206T3 (da) 2002-09-09
JP3657271B2 (ja) 2005-06-08
DE69622259T2 (de) 2003-03-27
NO973875D0 (no) 1997-08-22
CA2213798A1 (en) 1996-09-06
MX9706588A (es) 1997-11-29
AU699291B2 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
ES2179187T3 (es) Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
ATE163195T1 (de) Lösliche liganden für cd40
PT724456E (pt) Anticorpos contra cd4
DE69129989T2 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
EE9600192A (et) Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine
EA199800946A1 (ru) Концентрированный препарат антител
ATE212038T1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
NO971059L (no) Modifiserte human-C3-proteiner
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE59611293D1 (de) Protein mit dnase-aktivität
DE69118702T2 (de) Neue verwendung eines monoklonalen antikörpers
ES2067058T3 (es) Tratamiento de carnes.